[1]
|
Jemal, A., Bary, F., Center, M.M., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
|
[2]
|
韩仁强, 武鸣, 陈万青, 等. 2003-2007年中国前列腺癌发病与死亡分析[J]. 中国肿瘤, 2012, 21(11): 805-811.
|
[3]
|
韩苏军, 张思维, 陈万青, 等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013, 18(4): 330-334.
|
[4]
|
Beltran, H., Beer, T.M., Carducci, M.A., et al. (2011) New Therapies for Castrate Resistant Prostate Cancer: Efficacy and Safely. European Urology, 60, 279-290. https://doi.org/10.1016/j.eururo.2011.04.038
|
[5]
|
马春光, 叶定伟, 姚旭东, 等. 转移性前列腺癌生存预后分析[J]. 中华外科杂志, 2010, 48(15): 1166-1169.
|
[6]
|
王建伟, 周利群, 纪世祺, 等. 雌激素治疗激素难治性前列腺癌的疗效观察[J]. 中华医学杂志, 2011, 91(32): 2247-2249.
|
[7]
|
Lin, G.W., Yao, X.D., Zhang, S.L., et al. (2009) Prostate-Specific Antigen Half-Life: A New Predictor of Progression Free Survival and Overall Survival in Chinese Prostate Cancer Patients. Asian Journal of Andrology, 11, 443-450.
https://doi.org/10.1038/aja.2008.36
|
[8]
|
周浴, 李云飞. 间歇性多西他赛联合泼尼松治疗去势抵抗性前列腺癌初步研究[J]. 医学综述, 2014, 20(6): 1131-1133.
|
[9]
|
那彦群, 叶章群. 中国泌尿外科疾病诊段治疗指南(2014版) [M]. 北京: 人民教育出版社, 2014: 74.
|
[10]
|
丛树东, 吴光兴. 中晚期前列腺癌综合治疗及预后分析[J]. 中华肿瘤防治杂志, 2006, 13(22): 1760.
|
[11]
|
Nabhan, C., Pater, A., Villines, D., et al. (2014) Lenalidomide Monotherapy in Chemotherapy Naive, Castration Resistant Prostate Cancer Patients: Final Results of a Phase Ⅱ Study. Clinical Genitourinary Cancer, 12, 27-32.
https://doi.org/10.1016/j.clgc.2013.09.001
|
[12]
|
Tannock, I.F., Wit, R., Berry, W.J., et al. (2004) Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512.
https://doi.org/10.1056/NEJMoa040720
|
[13]
|
Petrylak, D.P., Tangen, C.M., Hussian, M.H., et al. (2004) Docet-axel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. New England Journal of Medicine, 351, 1513-1520.
https://doi.org/10.1056/NEJMoa041318
|
[14]
|
叶定伟, 朱一平. 激素抵抗性前列腺癌的治疗选择[J]. 现代泌尿外科杂志, 2011, 16(1): 6-7.
|
[15]
|
林国文, 叶定伟, 姚旭东, 等. 激素难治性前列腺癌患者化疗的预后分析[J]. 中华泌尿外科杂志, 2012, 33(1): 63-66.
|
[16]
|
Ranganathan, S., Benetatos, C.A., Colarusso, P.J., et al. (1998) Al-tered-Tubulin Isotype Expression in Paclitaxel Resistant Human Prostate Carcinoma Cells. British Journal of Cancer, 77, 562-566. https://doi.org/10.1038/bjc.1998.91
|
[17]
|
杨洋, 李良庆, 陈群, 等. ERCC1和TUBB3联合检测对晚期胃癌个体化治疗的应用分析[J]. 中国现代普通外科进展, 2014, 17(1): 20-23.
|
[18]
|
Roviello, G., Petrioli, R. and Francini, E. (2013) Time for a Revision on the Role of PSA Response Rate as a Surrogate Marker for Meddian Overall Survival in Docetaxel-Based First-Line Treatment for Patients with Metastatic Hormone-Refractory Prostate Cancer. International Journal of Biological Markers, 28, 326-328.
https://doi.org/10.5301/jbm.5000019
|
[19]
|
Olaussen, K.A., Dunant, A., Fouret, P., et al. (2006) DNA Repair by ERCC1 in Non Small Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. The New England Journal of Medicine, 355, 983.
https://doi.org/10.1056/NEJMoa060570
|